Editas Medicine, Inc.

XNASHealth care

Last traded price · USD

$2.62

−3.68%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 19:09 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $2.72
Volume: 498
Day's high: —
Day's low: —

In brief

Editas Medicine, Inc. is a health care company listed on Nasdaq, valued at about $402M.
Its shares closed at $2.72 on 4 Nov 2026, down 2.2% over the past year.
From India you can buy EDIT in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Editas Medicine, Inc. (EDIT) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole EDIT share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade EDIT options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Below its 50-day average, above its 200-day
The 4 Nov 2026 close of $2.72 was 0.4% below its 50-day average ($2.73) and 1.1% above its 200-day average ($2.69). It has closed above the 200-day for 1 session, since 4 Nov 2026. The 50-day average crossed above the 200-day on 5 May 2026, 127 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
14.3 days to cover short interest
38.2M shares were sold short at the 15 Oct 2026 settlement, 24.9% of the 153.6M shares outstanding; covering them would take 14.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Behind SPY and its sector fund XLV over 1 year
1 month: −0.4% (SPY −1.6%, XLV +13.5%). 3 months: −1.1% (SPY −0.4%, XLV +15.5%). 1 year: −2.2% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: EDIT, SPY and XLV · as of 4 Nov 2026
46% of the way up its 52-week range
Closed at $2.72 on 4 Nov 2026: 31.0% below the 52-week high of $3.94 (27 May 2026) and 63.9% above the low of $1.66 (5 Feb 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−0.4%

6 months−14.3%

1 year−2.2%

5 years−92.8%

Newswire

About

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

Website

Notable moves

August 13, 2025
+34.50%
February 20, 2025
−35.63%
February 19, 2025
+83.91%

Newswire

About

Website

Notable moves

August 13, 2025
+34.50%
February 20, 2025
−35.63%
February 19, 2025
+83.91%

Editas Medicine, Inc.

XNASHealth care

Last traded price · USD

$2.62

−3.68%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 19:09 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $2.72
Volume: 498
Day's high: —
Day's low: —

In brief

Editas Medicine, Inc. is a health care company listed on Nasdaq, valued at about $402M.
Its shares closed at $2.72 on 4 Nov 2026, down 2.2% over the past year.
From India you can buy EDIT in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Editas Medicine, Inc. (EDIT) shares from India?

Do I need the price of a whole EDIT share to invest?

How much can I invest in US stocks in a year?

Can I trade EDIT options or futures?

Insights

Quotes run fifteen minutes behind.

Below its 50-day average, above its 200-day
The 4 Nov 2026 close of $2.72 was 0.4% below its 50-day average ($2.73) and 1.1% above its 200-day average ($2.69). It has closed above the 200-day for 1 session, since 4 Nov 2026. The 50-day average crossed above the 200-day on 5 May 2026, 127 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
14.3 days to cover short interest
38.2M shares were sold short at the 15 Oct 2026 settlement, 24.9% of the 153.6M shares outstanding; covering them would take 14.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Behind SPY and its sector fund XLV over 1 year
1 month: −0.4% (SPY −1.6%, XLV +13.5%). 3 months: −1.1% (SPY −0.4%, XLV +15.5%). 1 year: −2.2% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: EDIT, SPY and XLV · as of 4 Nov 2026
46% of the way up its 52-week range
Closed at $2.72 on 4 Nov 2026: 31.0% below the 52-week high of $3.94 (27 May 2026) and 63.9% above the low of $1.66 (5 Feb 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−0.4%

6 months−14.3%

1 year−2.2%

5 years−92.8%

Newswire

About

Website

Notable moves

August 13, 2025
+34.50%
February 20, 2025
−35.63%
February 19, 2025
+83.91%

Newswire

About

Website

Notable moves

August 13, 2025
+34.50%
February 20, 2025
−35.63%
February 19, 2025
+83.91%

Editas Medicine, Inc.

Editas Medicine, Inc. in brief

Below its 50-day average, above its 200-day

14.3 days to cover short interest

Behind SPY and its sector fund XLV over 1 year

46% of the way up its 52-week range

Editas Medicine, Inc.

Editas Medicine, Inc. in brief

Below its 50-day average, above its 200-day

14.3 days to cover short interest

Behind SPY and its sector fund XLV over 1 year

46% of the way up its 52-week range